Survey: Compliance Programs Don’t Hurt Bottom Line, But Face Other Hurdles
This article was originally published in The Gray Sheet
Executive Summary
Nine out of 10 device and diagnostic firms responding to a survey say implementing a compliance program based on the 1AdvaMed Code of Ethics did not hurt their company's bottom line, including 10% who say their compliance program increased revenue
You may also be interested in...
Waxman’s Oversight Committee Looks Into Drug-Eluting Stents
The House Committee on Oversight and Government Reform is requesting information on the off-label use and marketing of drug-eluting stents
Device Firms Are Adopting And Promoting Ethics Standards, Survey Finds
A new survey suggests that medical device firms are complying with industry standards written to prevent fraudulent sales and marketing practices. Roughly 75% of surveyed companies said they post their compliance programs on the company website
ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: